OTCMKTS:BVNRY

Bavarian Nordic A/S (BVNRY) Stock Price, News & Analysis

$7.11
+0.16 (+2.30%)
(As of 04/22/2024 ET)
Today's Range
$7.04
$7.11
50-Day Range
$6.92
$8.53
52-Week Range
$5.95
$10.65
Volume
1,700 shs
Average Volume
5,440 shs
Market Capitalization
$1.67 billion
P/E Ratio
7.48
Dividend Yield
N/A
Price Target
N/A
BVNRY stock logo

About Bavarian Nordic A/S Stock (OTCMKTS:BVNRY)

Bavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.

Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.

The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.

The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. 

BVNRY Stock Price History

BVNRY Stock News Headlines

BVNKF Bavarian Nordic A/S
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Bavarian Nordic Publishes Annual Report 2023
Bavarian Nordic delivered record financial results in 2023
Bavarian Nordic delivered record financial results in 2023
Bavarian Nordic A/S ADR (BVNRY)
See More Headlines
Receive BVNRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bavarian Nordic A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:BVNRY
CIK
N/A
Employees
1,379
Year Founded
1994

Profitability

Net Income
$214.09 million
Pretax Margin
12.92%

Debt

Sales & Book Value

Annual Sales
$1.02 billion
Cash Flow
$0.04 per share
Book Value
$4.77 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.67 billion
Optionable
Not Optionable
Beta
1.50

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Paul John Chaplin MSc (Age 57)
    Ph.D., CEO & President
    Comp: $2.09M
  • Mr. Henrik Juuel M.Sc. (Age 59)
    CFO & Executive VP
    Comp: $1.16M
  • Mr. Russell Thirsk M.Sc. (Age 56)
    Executive VP & COO
  • Mr. Rolf Sass Sørensen
    Vice President of Investor Relations & Communications
  • Ms. Anu Helena Kerns M.Sc. (Age 52)
    Executive VP and Chief People & Sustainability Officer
  • Mr. Jean-Christophe May M.B.A. (Age 57)
    Pharm.D., Executive VP & Chief Commercial Officer
  • Dr. Laurence De Moerlooze Ph.D. (Age 60)
    Executive VP & Chief Medical Officer

BVNRY Stock Analysis - Frequently Asked Questions

How have BVNRY shares performed in 2024?

Bavarian Nordic A/S's stock was trading at $8.7450 at the start of the year. Since then, BVNRY shares have decreased by 18.7% and is now trading at $7.11.
View the best growth stocks for 2024 here
.

Are investors shorting Bavarian Nordic A/S?

Bavarian Nordic A/S saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 100 shares, a decrease of 98.1% from the March 15th total of 5,200 shares. Based on an average trading volume of 5,200 shares, the days-to-cover ratio is presently 0.0 days.
View Bavarian Nordic A/S's Short Interest
.

How were Bavarian Nordic A/S's earnings last quarter?

Bavarian Nordic A/S (OTCMKTS:BVNRY) released its earnings results on Wednesday, March, 6th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.12. The firm earned $353.27 million during the quarter, compared to analyst estimates of $340.71 million. Bavarian Nordic A/S had a net margin of 20.80% and a trailing twelve-month return on equity of 0.07%.

How do I buy shares of Bavarian Nordic A/S?

Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BVNRY) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners